Furosemide

Brand (proprietary) name

None — marketed under its generic name

Generic (nonproprietary) name

Furosemide

Active ingredient(s)

furosemide

Strength(s)

10 mg/mL; 100 mg/10mL; 20 mg/2mL; 40 mg/4mL

Dosage form(s)

Injection; Injection, Solution

Route(s)

Intramuscular; Intravenous

Manufacturer / labeler

Hikma Pharmaceuticals USA Inc.Henry Schein, Inc.Hospira, Inc.Accord Healthcare Inc.Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.Sagent PharmaceuticalsCamber Pharmaceuticals, Inc.Baxter Healthcare CorporationMicro Labs LimitedHF Acquisition Co LLC, DBA HealthFirstGeneral Injectables and Vaccines, Inc.Eugia US LLCCardinal Health 107, LLCFresenius Kabi USA, LLCGland Pharma LimitedAmneal Pharmaceuticals LLCREMEDYREPACK INC.Lifestar Pharma LLCAthenex Pharmaceutical Division, LLC.Meitheal Pharmaceuticals Inc.Medical Purchasing Solutions, LLCCivica, Inc.NorthStar Rx LLCDevatis Inc.Maiva Pharma Private LimitedPhlow CorporationAvenacy, LLCProPharma Distribution

Product class

Generic (ANDA) (derived from FDA marketing category)

Marketing category

ANDA; NDA

Application number(s)

ANDA070017, ANDA075241, ANDA202747, ANDA203428, ANDA207552, ANDA212174, ANDA212803, ANDA213902, ANDA214766, ANDA215856, ANDA216860, ANDA217557, ANDA218188, NDA018267, NDA018667, NDA018902

Earliest marketing start

Jul 12, 2000

Products / packages indexed

89 / 122

FDA pharmacologic class: Increased Diuresis at Loop of Henle [PE]; Loop Diuretic [EPC]

Also searchable as: Furosemide · FUROESEMIDE

Prescribing information on DailyMed (NLM)

• J1938JJ-code: Drugs administered other than oral method; chemotherapy drugsActiveDerived calculation

  Injection, furosemide, 1 mg

  Derived: 61 of 122 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J1938. CMS quarters Q2 2025 – Q4 2026

  J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.

• J1940JJ-code: Drugs administered other than oral method; chemotherapy drugs

No authoritative public data was located for this field.

Which Medicare benefit pays for this drug?

• Coverage documents for furosemide NCDs, LCDs, and Billing & Coding articles in the CMS Medicare Coverage Database that mention “furosemide”. Covered diagnosis codes are listed in the articles.
• Coverage documents for J1938 NCDs, LCDs, and Billing & Coding articles in the CMS Medicare Coverage Database that mention “J1938”. Covered diagnosis codes are listed in the articles.

No current Medicare Billing and Coding article lists J1938, J1940.

• FDA NDC Directory data is submitted by labelers; FDA notes that inclusion does not mean the information was verified or that a product is approved, covered, or reimbursable.
• HCPCS links are derived from CMS NDC–HCPCS crosswalks, which support ASP-based Part B payment and are not a complete list of billable NDCs.
• Product class (brand, generic, biosimilar) is derived from the FDA marketing category and Purple Book license type, not from a commercial compendium.
• Payment limits are Medicare Part B national limits; they do not reflect payer contracts, OPPS rates, 340B pricing, or acquisition cost.
• Home infusion per diem S-codes are matched by therapy category from the FDA pharmacologic class and route, not from a CMS crosswalk. Payers choose which per diem codes they accept, and the right code can depend on the dosing schedule, infusion method, or daily volume.